USFDA declined the approval of Pfizer’s Herceptin biosimilar for breast cancer treatment.
Pfizer’s biosimilar-PF-05280014 has shown equivalence in the objective response rate with Herceptin in HER2-positive metastatic breast cancer patients in clinical studies.
Roche’s top-selling rheumatoid arthritis drug, Rituxan® (rituximab) received US FDA Priority Review status for the treatment of pemphigus vulgaris (PV), ...